Gossamer Bio, Inc. (NASDAQ:GOSS – Get Rating) Chief Financial Officer Bryan Giraudo purchased 13,869 shares of the company in a trade that took place Friday, July 15. The shares were acquired at an average price of $7.21 per share, with a total value of $99,995.49. Following the completion of the transaction, the CFO now directly owns 20,990 shares of the company, valued at $151,337.90. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.
Gossamer Bio Stock Up to 0.3%
GOSS stock opened at $11.08 on Friday. The stock has a market capitalization of $854.49 million, a P/E ratio of -3.57 and a beta of 0.85. The company has a 50-day simple moving average of $7.60 and a 200-day simple moving average of $8.74. The company has a quick ratio of 8.12, a current ratio of 8.12 and a debt ratio of 7.44. Gossamer Bio, Inc. has a 52 week low of $5.64 and a 52 week high of $14.30.
Gossamer Bio (NASDAQ:GOSS – Get Rating) last released its results on Tuesday, May 10. The company reported ($0.76) EPS for the quarter, beating analyst consensus estimates of ($0.77) by $0.01. Stock analysts expect Gossamer Bio, Inc. to post earnings per share of -2.73 for the current fiscal year.
Institutional trading of Gossamer Bio
Several large investors have recently bought and sold shares of GOSS. Woodline Partners LP acquired a new stake in Gossamer Bio during Q4, valued at approximately $11,059,000. Kynam Capital Management LP increased its stake in Gossamer Bio by 80.2% during the 1st quarter. Kynam Capital Management LP now owns 1,832,704 shares of the company valued at $15,908,000 after acquiring an additional 815,847 shares last quarter. Federated Hermes Inc. increased its stake in Gossamer Bio by 19.0% in the 1st quarter. Federated Hermes Inc. now owns 3,526,478 shares of the company valued at $30,610,000 after acquiring an additional 564,236 shares last quarter. Eversept Partners LP increased its stake in Gossamer Bio by 838.9% in the 1st quarter. Eversept Partners LP now owns 374,723 shares of the company valued at $3,253,000 after acquiring an additional 334,813 shares last quarter. Finally, Emerald Advisers LLC increased its stake in Gossamer Bio by 16.8% during the 4th quarter. Emerald Advisers LLC now owns 1,770,919 shares of the company valued at $20,029,000 after acquiring an additional 254,916 shares last quarter. Hedge funds and other institutional investors hold 76.90% of the company’s shares.
Analysts set new price targets
A number of research analysts have weighed in on the stock. Raymond James raised his price target on Gossamer Bio shares from $10.00 to $14.00 and gave the company an “outperform” rating in a report released Thursday. Cantor Fitzgerald reaffirmed an “overweight” rating on Gossamer Bio shares in a Monday, May 9 report. Piper Sandler cut her price target on shares of Gossamer Bio from $26.00 to $15.00 in a Monday, April 25 report. HC Wainwright reaffirmed a “buy” rating and issued a price target of $20.00 on shares of Gossamer Bio in a report Thursday. Finally, UBS Group assumed coverage for Gossamer Bio shares in a report on Wednesday, April 6. They issued a “buy” rating and a price target of $19.00 for the company. Nine equity research analysts rated the stock with a buy rating. According to data from MarketBeat.com, the stock currently has a consensus buy rating and a consensus price target of $18.00.
About Gossamer Bio
(Get an assessment)
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, is focused on the discovery, acquisition, development and commercialization of therapeutics in the areas of immunology, inflammation and oncology in the United States. United. The Company is developing GB002, an inhaled small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, an oral small molecule targeting the gut for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent small molecule Bruton’s tyrosine kinase inhibitor for the treatment of primary central nervous system lymphoma; and GB7208, an oral small molecule BTK inhibitor for the treatment of multiple sclerosis.
Get news and reviews for Gossamer Bio Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Gossamer Bio and related companies with MarketBeat.com’s free daily email newsletter.